Latest Accelrys Inc (ACCL) Headlines
Is More Good News Ahead for Recent Winner Guidewire Software (GWRE)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:57AM CDT
Guidewire Software has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy
Uptrend Call Working As Accelrys Stock Rises 33.4% (ACCL)
Comtex SmarTrend(R) - Mon Mar 10, 9:45AM CDT
SmarTrend identified an Uptrend for Accelrys (NASDAQ:ACCL) on September 16th, 2013 at $9.37. In approximately 6 months, Accelrys has returned 33.37% as of today's recent price of $12.49.
Research and Markets: Global Biosimulation Market Forecasts & Opportunities, 2018: Accelrys, Certara, Schrodinger & Simulation Plus Dominate
Business Wire - Mon Mar 10, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/57m7rs/global) has announced the addition of the "Global Biosimulation Market Forecasts & Opportunities to 2018: Accelrys, Certara, Schrodinger & Simulation Plus Dominate" report to their offering.
Global Biosimulation Market Forecasts & Opportunities, 2018: Accelrys, Certara, Schrodinger & Simulation Plus Dominate
M2 - Mon Mar 10, 9:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f24tx8/global) has announced the addition of the "Global Biosimulation Market Forecasts & Opportunities to 2018: Accelrys, Certara, Schrodinger & Simulation Plus Dominate" report to their offering. The Global Biosimulation market is witnessing increasing collaborations and partnerships between vendors. Such collaborations are aiding innovation in the market. For instance, Genedata is collaborating with Insilico Biotechnology AG, which is a Germany-based provider of software and solutions for the simulation of living cells, to support life science companies in improving and enhancing their biotechnological production methods. Additionally, a number of vendors in the Global Biosimulation market collaborate with pharmaceutical companies. For instance, in May 2013, Accelrys Inc., a US-based provider of scientific enterprise software, signed a three-year agreement with Pfizer Inc., a pharmaceutical company, for the use of its products such as, modeling and simulation software, by Pfizer's researchers worldwide. According to the report, one of the most important drivers is the reduction in the drug discovery and development costs of pharmaceutical companies as a result of deploying biosimulation software solutions during the R&D process. Since such software brings about an understanding of clinical outcomes before human trials, their use adds immense value to pharmaceutical companies involved in the R&D of drugs, and helps companies reduce costs. Further, the report states that one of the major challenges in the market is the high R&D costs associated with the development of biosimulation software. Several biosimulation models offer a virtual patient population to aid the development and testing of drugs, but these models are constructed using a large amount of data, which increases costs. The key vendors dominating this market space are: - Accelrys Inc. - Certara L.P. - Schrodinger Llc - Simulation Plus Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Application 08. Market Segmentation by Approach to Model Development 09. Market Segmentation by Scale of Biosimulation 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/f24tx8/global
Cyan (CYNI) Soars: Stock Adds 19.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:51AM CST
Cyan, Inc. was a big mover last session, as its shares rose nearly 20% on the day.
Global Bioinformatics Market 2014-2018 with Accelrys, Affymetrix, Agilent, CLCbio A/S & Illumina Dominating
M2 - Thu Mar 06, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5lxv6/global) has announced the addition of the "Global Bioinformatics Market 2014-2018 with Accelrys, Affymetrix, Agilent, CLCbio A/S & Illumina Dominating" report to their offering. The Global Bioinformatics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC region; it also covers the Global Bioinformatics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. As a result of declining budgets for R&D, biotechnology companies and other organizations are seeking ways to increase efficiency by outsourcing bioinformatics to effectively support their R&D activities at less cost. Also, outsourcing may be an increasingly viable option for research organizations which lack the requisite computational infrastructure and informatics expertise for bioinformatics tools in house. Outsourcing the services to a third-party vendor can allow an organization to refocus on key projects that contribute to increasing the effectiveness of its R&D and shorten development-to-launch timelines. One of the major drivers in this market is the decreasing cost of genetic sequencing. This reduction in cost is a result of the development of tools and technologies as well as the improvements in processes made by genomics researchers. The report states that one of the major challenges in the market is the growing complexity in using bioinformatics tools and the consequent need for proper training and guidance to use these tools properly and efficiently. The key vendors dominating this market space are: - Accelrys Inc. - Affymetrix Inc. - Agilent Technologies Inc. - CLCbio A/S - Illumina Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Application 08. Market Segmentation by Products and Services 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/r5lxv6/global
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Amtech Systems (ASYS) Jumps: Stock Rises 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:18AM CST
Amtech Systems Inc. (ASYS) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
Looking for a Growth Stock? Why It is Time to Focus on Accelrys (ACCL) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:54AM CST
Accelrys is well-positioned for future earnings growth and could be a strong growth stock contender
Amneal Pharmaceuticals Implements QUMAS Compliance and Quality Management Solution
Marketwire - Tue Mar 04, 7:48AM CST
QUMAS, an Accelrys company (NASDAQ: ACCL), today announced that Amneal Pharmaceuticals LLC is now leveraging QUMAS DocCompliance and ProcessCompliance to manage all quality documents and resolve any customer issues across ten facilities located in the U.S. and India. According to IMS Health, Amneal is the 7th largest generic drug manufacturer in the U.S. market based on number of prescriptions dispensed.
Accelrys Capture Drives Next-generation Mobility in the Laboratory
PR Newswire - Mon Mar 03, 7:00AM CST
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced its next-generation mobile strategy for the laboratory--to provide a flexible and secure mobile computing environment that effectively connects scientists, equipment and materials in today's laboratories where an increasing number and variety of mobile devices, from smart phones to tablet computers, are in use. With over a decade of experience in pioneering paperless, mobile computing and wireless compliance capabilities in regulated laboratories, Accelrys will empower organizations to deploy purpose-built mobile applications in the lab from research to manufacturing, satisfying specific workflow requirements in accordance with Good Manufacturing Practice. Further advancing this mobile strategy, Accelrys Capture is a new mobile multi-media capture application that facilitates rapid, paperless recording at the laboratory bench, significantly improving workflow flexibility, efficiency and productivity.
Accelrys Notebook 5.0 Sets New Standards for Moving from Paper-Based to Digital Laboratories
M2 - Thu Feb 27, 9:30AM CST
Accelrys, Inc. (NASDAQ: ACCL) said it has released Accelrys Notebook 5.0, a flexible, multi-discipline electronic laboratory notebook with significant new capabilities for customizing work environments and connecting to existing laboratory software without complex integration and advanced programming support.
Is This the Top for Accelrys (ACCL)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:57AM CST
Is This the Top for Accelrys (ACCL)?
INVESTOR ALERT - ACCELRYS INC: The Law Offices of Vincent Wong Investigates the Sale of ACCELRYS INC. to Dassault Systemes SA -- ACCL
Business Wire - Wed Feb 26, 10:58AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Accelrys Inc. (Nasdaq:ACCL) ("Accelrys") in connection with the sale of the Company to Dassault Systemes SA.
Accelrys Announces Fourth Quarter and Full Year 2013 Results
Business Wire - Tue Feb 25, 3:05PM CST
Accelrys, Inc. (NASDAQ: ACCL) today reported financial results for the fiscal quarter ended December 31, 2013. Non-GAAP revenue for the quarter ended December 31, 2013 increased to $47.6 million from $47.5 million for the same quarter of the previous year. Non-GAAP revenue for the year ended December 31, 2013 increased $3.4 million to $177.7 million from $174.3 million for the year ended December 31, 2012 or an increase of 1.9 percent.
33.4% Return Seen to Date on SmarTrend Accelrys Call (ACCL)
Comtex SmarTrend(R) - Fri Feb 21, 4:55PM CST
SmarTrend identified an Uptrend for Accelrys (NASDAQ:ACCL) on September 16th, 2013 at $9.37. In approximately 5 months, Accelrys has returned 33.37% as of today's recent price of $12.49.
Accelrys-sponsored Presentations at SmartLab Exchange Span Research and Laboratory Informatics
PR Newswire - Wed Feb 19, 7:00AM CST
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced that it is sponsoring four talks at the 9th Annual SmartLab Exchange to be held on February 25-26 in Munich. As Europe's premier laboratory informatics event, SmartLab Exchange provides a valuable opportunity for specialists in the pharmaceutical/biotech, food and beverage, consumer packaged goods, cosmetics, healthcare, chemicals and oil and gas industries to discuss current and future trends in the evolving lab informatics market including lab automation, the paperless lab, knowledge sharing and strategic data management.
Is More Good News Ahead for Recent Winner Guidewire Software (GWRE)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:57AM CDT
Guidewire Software has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy
Uptrend Call Working As Accelrys Stock Rises 33.4% (ACCL)
Comtex SmarTrend(R) - Mon Mar 10, 9:45AM CDT
SmarTrend identified an Uptrend for Accelrys (NASDAQ:ACCL) on September 16th, 2013 at $9.37. In approximately 6 months, Accelrys has returned 33.37% as of today's recent price of $12.49.
Research and Markets: Global Biosimulation Market Forecasts & Opportunities, 2018: Accelrys, Certara, Schrodinger & Simulation Plus Dominate
Business Wire - Mon Mar 10, 9:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/57m7rs/global) has announced the addition of the "Global Biosimulation Market Forecasts & Opportunities to 2018: Accelrys, Certara, Schrodinger & Simulation Plus Dominate" report to their offering.
Global Biosimulation Market Forecasts & Opportunities, 2018: Accelrys, Certara, Schrodinger & Simulation Plus Dominate
M2 - Mon Mar 10, 9:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f24tx8/global) has announced the addition of the "Global Biosimulation Market Forecasts & Opportunities to 2018: Accelrys, Certara, Schrodinger & Simulation Plus Dominate" report to their offering. The Global Biosimulation market is witnessing increasing collaborations and partnerships between vendors. Such collaborations are aiding innovation in the market. For instance, Genedata is collaborating with Insilico Biotechnology AG, which is a Germany-based provider of software and solutions for the simulation of living cells, to support life science companies in improving and enhancing their biotechnological production methods. Additionally, a number of vendors in the Global Biosimulation market collaborate with pharmaceutical companies. For instance, in May 2013, Accelrys Inc., a US-based provider of scientific enterprise software, signed a three-year agreement with Pfizer Inc., a pharmaceutical company, for the use of its products such as, modeling and simulation software, by Pfizer's researchers worldwide. According to the report, one of the most important drivers is the reduction in the drug discovery and development costs of pharmaceutical companies as a result of deploying biosimulation software solutions during the R&D process. Since such software brings about an understanding of clinical outcomes before human trials, their use adds immense value to pharmaceutical companies involved in the R&D of drugs, and helps companies reduce costs. Further, the report states that one of the major challenges in the market is the high R&D costs associated with the development of biosimulation software. Several biosimulation models offer a virtual patient population to aid the development and testing of drugs, but these models are constructed using a large amount of data, which increases costs. The key vendors dominating this market space are: - Accelrys Inc. - Certara L.P. - Schrodinger Llc - Simulation Plus Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Application 08. Market Segmentation by Approach to Model Development 09. Market Segmentation by Scale of Biosimulation 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/f24tx8/global
Cyan (CYNI) Soars: Stock Adds 19.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:51AM CST
Cyan, Inc. was a big mover last session, as its shares rose nearly 20% on the day.
Global Bioinformatics Market 2014-2018 with Accelrys, Affymetrix, Agilent, CLCbio A/S & Illumina Dominating
M2 - Thu Mar 06, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5lxv6/global) has announced the addition of the "Global Bioinformatics Market 2014-2018 with Accelrys, Affymetrix, Agilent, CLCbio A/S & Illumina Dominating" report to their offering. The Global Bioinformatics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC region; it also covers the Global Bioinformatics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. As a result of declining budgets for R&D, biotechnology companies and other organizations are seeking ways to increase efficiency by outsourcing bioinformatics to effectively support their R&D activities at less cost. Also, outsourcing may be an increasingly viable option for research organizations which lack the requisite computational infrastructure and informatics expertise for bioinformatics tools in house. Outsourcing the services to a third-party vendor can allow an organization to refocus on key projects that contribute to increasing the effectiveness of its R&D and shorten development-to-launch timelines. One of the major drivers in this market is the decreasing cost of genetic sequencing. This reduction in cost is a result of the development of tools and technologies as well as the improvements in processes made by genomics researchers. The report states that one of the major challenges in the market is the growing complexity in using bioinformatics tools and the consequent need for proper training and guidance to use these tools properly and efficiently. The key vendors dominating this market space are: - Accelrys Inc. - Affymetrix Inc. - Agilent Technologies Inc. - CLCbio A/S - Illumina Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Application 08. Market Segmentation by Products and Services 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/r5lxv6/global
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Amtech Systems (ASYS) Jumps: Stock Rises 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:18AM CST
Amtech Systems Inc. (ASYS) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
Looking for a Growth Stock? Why It is Time to Focus on Accelrys (ACCL) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:54AM CST
Accelrys is well-positioned for future earnings growth and could be a strong growth stock contender
Amneal Pharmaceuticals Implements QUMAS Compliance and Quality Management Solution
Marketwire - Tue Mar 04, 7:48AM CST
QUMAS, an Accelrys company (NASDAQ: ACCL), today announced that Amneal Pharmaceuticals LLC is now leveraging QUMAS DocCompliance and ProcessCompliance to manage all quality documents and resolve any customer issues across ten facilities located in the U.S. and India. According to IMS Health, Amneal is the 7th largest generic drug manufacturer in the U.S. market based on number of prescriptions dispensed.
Accelrys Capture Drives Next-generation Mobility in the Laboratory
PR Newswire - Mon Mar 03, 7:00AM CST
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced its next-generation mobile strategy for the laboratory--to provide a flexible and secure mobile computing environment that effectively connects scientists, equipment and materials in today's laboratories where an increasing number and variety of mobile devices, from smart phones to tablet computers, are in use. With over a decade of experience in pioneering paperless, mobile computing and wireless compliance capabilities in regulated laboratories, Accelrys will empower organizations to deploy purpose-built mobile applications in the lab from research to manufacturing, satisfying specific workflow requirements in accordance with Good Manufacturing Practice. Further advancing this mobile strategy, Accelrys Capture is a new mobile multi-media capture application that facilitates rapid, paperless recording at the laboratory bench, significantly improving workflow flexibility, efficiency and productivity.
Accelrys Notebook 5.0 Sets New Standards for Moving from Paper-Based to Digital Laboratories
M2 - Thu Feb 27, 9:30AM CST
Accelrys, Inc. (NASDAQ: ACCL) said it has released Accelrys Notebook 5.0, a flexible, multi-discipline electronic laboratory notebook with significant new capabilities for customizing work environments and connecting to existing laboratory software without complex integration and advanced programming support.
Is This the Top for Accelrys (ACCL)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 7:57AM CST
Is This the Top for Accelrys (ACCL)?
INVESTOR ALERT - ACCELRYS INC: The Law Offices of Vincent Wong Investigates the Sale of ACCELRYS INC. to Dassault Systemes SA -- ACCL
Business Wire - Wed Feb 26, 10:58AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Accelrys Inc. (Nasdaq:ACCL) ("Accelrys") in connection with the sale of the Company to Dassault Systemes SA.
Accelrys Announces Fourth Quarter and Full Year 2013 Results
Business Wire - Tue Feb 25, 3:05PM CST
Accelrys, Inc. (NASDAQ: ACCL) today reported financial results for the fiscal quarter ended December 31, 2013. Non-GAAP revenue for the quarter ended December 31, 2013 increased to $47.6 million from $47.5 million for the same quarter of the previous year. Non-GAAP revenue for the year ended December 31, 2013 increased $3.4 million to $177.7 million from $174.3 million for the year ended December 31, 2012 or an increase of 1.9 percent.
33.4% Return Seen to Date on SmarTrend Accelrys Call (ACCL)
Comtex SmarTrend(R) - Fri Feb 21, 4:55PM CST
SmarTrend identified an Uptrend for Accelrys (NASDAQ:ACCL) on September 16th, 2013 at $9.37. In approximately 5 months, Accelrys has returned 33.37% as of today's recent price of $12.49.
Accelrys-sponsored Presentations at SmartLab Exchange Span Research and Laboratory Informatics
PR Newswire - Wed Feb 19, 7:00AM CST
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced that it is sponsoring four talks at the 9th Annual SmartLab Exchange to be held on February 25-26 in Munich. As Europe's premier laboratory informatics event, SmartLab Exchange provides a valuable opportunity for specialists in the pharmaceutical/biotech, food and beverage, consumer packaged goods, cosmetics, healthcare, chemicals and oil and gas industries to discuss current and future trends in the evolving lab informatics market including lab automation, the paperless lab, knowledge sharing and strategic data management.
